natgillin/translations-raw huggingface dataset:
Clinically validated phenotypic interpretation systems may be used in association with the genotypic data to estimate the activity of amprenavir / ritonavir or fosamprenavir / ritonavir in patients with PIresistant isolates. 
Za procjenu aktivnosti amprenavira/ritonavira ili fosamprenavira/ritonavira kod bolesnika s izolatima otpornim na IP mogu se koristiti klinički validirani sistemi za fenotipsku interpretaciju.
225 ml oral suspension A 10 ml graduated dosing syringe and adapter are also provided in the pack 
U pakiranju se također nalaze graduirana odmjerna štrcaljka od 10 ml i nastavak
Flecainide: ↑ expected 
Flutikazon propionat
Elderly 
Ranitidin
Change from baseline in CD4 cells (cells/µl) 
Promjena od početnih vrijednosti CD4
If you have mild liver disease, the dose is one Telzir tablet (700 mg) twice daily with 100 mg ritonavir only once daily. 
Ako bolujete od blage bolesti jetre, doza je jedna tableta lijeka Telzir (700 mg) dva puta dnevno s
Rapamycin 
Rifampicin
b) PI-experienced patients 
b) bolesnici koji su ranije primali IP terapiju
Lamivudine 
Efavirenz
AAUCMB Mean Diff (97.5% CI) 
FPV/RTV BID naspram LPV/RTV BID AAUCMB Srednja vrijednost razlike (97,5% CI)
33-38 kg Oral suspension 
225 ml oralne suspenzije
When warfarin or other oral anticoagulants are coadministered with Telzir a reinforced monitoring of INR (International Normalised Ratio) is recommended (see section 4.5). 
International normalised ratio) u slučajevima kada se istodobno s lijekom Telzir primjenjuje varfarin ili drugi oralni antikoagulansi (vidjeti dio 4.5).
Harmire Road Barnard Castle Co. Durham DL12 8DT United Kingdom 
Durham DL12 8DT Ujedinjeno Kraljevstvo ili
90 x 1 tablets (unit dose) 
90x1 tableta obložene tablete
Powder for oral suspension bottle (glass) 
10 mg/ml prašak za oralnu suspenziju
Solution for injection Intravenous use vial (glass) 
0,8 mg/ml otopina za injekciju u venu
How much to take and when 
Koliko uzeti i kada
Additional information on special populations Elderly (≥ 65 years) 
Dodatne informacije o posebnim populacijama Starije osobe (≥65 godina)
Medical attention may be needed. 
Možda će biti potrebna medicinska pomoć.
However, this has not been established in the target population. 
To, međutim, nije ustanovljeno u ciljnoj populaciji.
Statistical non-inferiority was not achieved. 
Nije postignuta statistička neinferiornost.
The absolute bioavailability is 85%. 
Apsolutna bioraspoloživost je 85%.
Then take your next dose at the usual time. 
Nakon toga sljedeću dozu uzmite u uobičajeno vrijeme.
112 tablets. 
112 tableta.
Your doctor will tell you exactly how many tablets of Jalra to take. 
Liječnik će Vam reći točno koliko tableta Jalre trebate uzimati.
You may have to take this treatment over a long period of time. 
Ovu terapiju ćete možda morati uzimati kroz duže vremensko razdoblje.
If you take more Jalra than you should 
Ako uzmete više Jalre nego što ste trebali
Adjudicated cardiovascular events were balanced overall. 
Procijenjeni kardiovaskularni događaji bili su općenito uravnoteženi.
These changes are, however, not considered to be clinically relevant. 
Ove se promjene, međutim, ne smatraju klinički značajnim.
Do not stop taking Jalra unless your doctor tells you to. 
Nemojte prestati uzimati Jalru osim ako Vam to ne kaže liječnik.
If you need to see a doctor or go to the hospital, take the pack with you. 
Ako trebate otići liječniku ili u bolnicu, pakovanje ponesite sa sobom.
The maximum daily dose is 100 mg. 
Maksimalna dnevna doza je 100 mg.
A double dose should not be taken on the same day. 
U istom se danu ne smije uzeti dvostruka doza lijeka.
What Jalra is and what it is used for 
Što je Jalra i za što se koristi
If it is almost time for your next dose, skip the dose you missed. 
Ako je uskoro vrijeme za Vašu sljedeću dozu, preskočite dozu koju ste propustili uzeti.
If you have questions about how long to take this medicine, talk to your doctor. 
Ako imate pitanja o tome koliko dugo trebate uzimati ovaj lijek, obratite se svom liječniku.
Doses higher than 100 mg are not recommended. 
Ne preporučuju se doze veće od 100 mg.
Even though you are now starting a medicine for your diabetes, it is important that you continue to follow the diet and/or exercise which has been recommended for you. 
Iako sada počinjete uzimati lijek za svoju šećernu bolest, važno je da se nastavite pridržavati prehrane i/ili fizičke aktivnosti koja Vam je preporučena.
Date of first authorisation: 19 November 2008 Date of latest renewal: 28 November 2013 
Datum posljednje obnove odobrenja: 28. studenog 2013.
The expiry date refers to the last day of that month. 
“EXP“- Rok valjanosti odnosi se na zadnji dan navedenog mjeseca.
• if you are allergic to vildagliptin or any of the other ingredients of this medicine (listed in section 6). 
• ako ste alergični na vildagliptin ili neki drugi sastojak ovog lijeka (naveden u dijelu 6).
The amount of Jalra people have to take varies depending on their condition. 
Količina Jalre koju ljudi moraju uzimati ovisi o njihovu stanju.
Multipack: 336 (3 packs of 112) tablets. 
Višestruko pakiranje: 336 (3 pakiranja od 112) tableta.
Characteristics in specific groups of patients 
Svojstva u posebnim skupinama bolesnika
Rare cases of hepatic dysfunction (including hepatitis) have been reported. 
Rijetko su bili prijavljeni slučajevi poremećaja jetrene funkcije (uključujući hepatitis).
If you forget to take a dose of this medicine, take it as soon as you remember. 
Ako ste zaboravili uzeti dozu ovoga lijeka, uzmite ju čim se sjetite.
• Your doctor will regularly monitor your condition to check that the treatment is having the desired effect. 
Vaše stanje kako bi utvrdio ima li liječenje željeni učinak.
EU/1/08/485/011 336 tablets (3 packs of 112) 
EU/1/08/485/011 336 tableta (3 pakiranja od 112)
In the event of an overdose, supportive management is recommended. 
U slučaju predoziranja preporučuje se suportivno liječenje.
Frequencies are defined as very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data). 
Učestalost se definira kao vrlo često (≥1/10), često (≥1/100 i <1/10), manje često (≥1/1000 i <1/100), rijetko (≥1/10 000 i <1/1000), vrlo rijetko (<1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
What you need to know before you take Jalra 
Što morate znati prije nego počnete uzimati Jalru
However, there were imbalances in baseline cardiovascular risk favouring placebo and the number of events was low, precluding firm conclusions. 
Međutim, postojale su nejednakosti u početnom kardiovaskularnom riziku u korist placeba, a broj događaja bio je nizak, što onemogućuje čvrste zaključke.
The usual dose of Jalra is either: 
Uobičajena doza Jalre iznosi ili:
No data are available (see also section 5.1). 
Nema dostupnih podataka (vidjeti također dio 5.1).
However, the magnitude of change is not clinically significant, so that Jalra can be given with or without food. 
Međutim, stupanj promjene nije klinički značajan pa se Jalra može primjenjivati s hranom ili bez nje.
If you take too many Jalra tablets, or if someone else has taken your medicine, talk to your doctor straight away. 
Ako uzmete previše tableta Jalre, ili ako je netko drugi uzeo Vaš lijek, odmah se javite svom liječniku.
EU/1/08/485/001 7 tablets EU/1/08/485/002 14 tablets EU/1/08/485/003 28 tablets EU/1/08/485/004 30 tablets EU/1/08/485/005 56 tablets EU/1/08/485/006 60 tablets EU/1/08/485/007 90 tablets EU/1/08/485/008 112 tablets EU/1/08/485/009 180 tablets EU/1/08/485/010 336 tablets 
EU/1/08/485/001 7 tableta EU/1/08/485/002 14 tableta EU/1/08/485/003 28 tableta EU/1/08/485/004 30 tableta EU/1/08/485/005 56 tableta EU/1/08/485/006 60 tableta EU/1/08/485/007 90 tableta EU/1/08/485/008 112 tableta EU/1/08/485/009 180 tableta EU/1/08/485/010 336 tableta
The maximum change (increase or decrease) in the exposure to vildagliptin is ~30%, which is not considered to be clinically relevant. 
Maksimalna promjena (porast ili smanjenje) izloženosti vildagliptinu iznosi ~30%, što se ne smatra klinički značajnim.
• Take Jalra every day for as long as your doctor tells you. 
• Jalru uzimajte svaki dan onoliko dugo koliko Vam liječnik kaže.
You are also advised to pay particular attention to new onset of blisters or ulcers while taking Jalra. 
Također Vam se savjetuje da posvetite posebnu pozornost novoj pojavi mjehurića ili čireva dok uzimate Jalru.
• The active substance is vildagliptin. 
• Djelatna stvar je vildagliptin.
• if you are on dialysis. 
• ako ste na dijalizi.
Jalra is not a substitute for insulin in insulin-requiring patients. 
Jalra nije zamjena za inzulin u bolesnika koji trebaju inzulin.
Administration of vildagliptin with food resulted in a decreased Cmax (19%). 
Primjena vildagliptina s hranom rezultira smanjenim Cmax (19%).
Digoxin (Pgp substrate), warfarin (CYP2C9 substrate) 
Digoksin (Pgp supstrat), varfarin (CYP2C9 supstrat)
• if you have type 1 diabetes (i.e. your body does not produce insulin) or if you have a condition called diabetic ketoacidosis. 
• ako imate šećernu bolest tipa 1 (odnosno Vaše tijelo ne stvara inzulin) ili ako imate stanje koje se zove dijabetička ketoacidoza
It is used when diabetes cannot be controlled by diet and exercise alone. 
Primjenjuje se kada se šećerna bolest ne može kontrolirati samo dijetom i tjelovježbom.
One side is debossed with “NVR”, and the other side with “FB”. 
Na jednoj je strani utisnuta oznaka „NVR“, a na drugoj strani „FB“.
What Jalra is and what it is used for What you need to know before you take Jalra How to take Jalra 
Što je Jalra i za što se koristi Što morate znati prije nego počnete uzimati Jalru
However, the major hydrolysis metabolite (LAY 151) can be removed by haemodialysis. 
No, glavni se metabolit hidrolize (LAY 151) može ukloniti hemodijalizom.
Insulin is a substance which helps to lower the level of sugar in the blood, especially after meals. 
Inzulin je tvar koja pomaže u snižavanju razine šećera u krvi, osobito poslije obroka.
Talk to your doctor, pharmacist or nurse before taking Jalra. 
Obratite se svom liječniku, ljekarniku ili medicinskoj sestri prije nego uzmete Jalru
What Jalra looks like and contents of the pack 
Kako Jalra izgleda i sadržaj pakiranja
Some symptoms need immediate medical attention: You should stop taking Jalra and see your doctor immediately if you experience the following side effects: 
Neki simptomi zahtijevaju hitnu medicinsku pomoć: Prestanite uzimati Jalru i odmah otiđite svom liječniku ako osjetite sljedeće nuspojave:
Embryo-foetal toxicity was evaluated in rats and rabbits. 
Embriofetalna toksičnost je ispitivana u štakora i kunića.
Your doctor may wish to alter your dose of Jalra if you are taking other medicines such as: - thiazides or other diuretics (also called water tablets) - corticosteroids(generally used to treat inflammation) - thyroid medicines - certain medicines affecting the nervous system. 
Liječnik će Vam možda željeti promijeniti dozu Jalre ako uzimate druge lijekove kao što su: - tijazidi ili drugi diuretici (također se zovu tablete za vodu) - kortikosteroidi (općenito se koristeza liječenje upale) - lijekovi za liječenje štitnjače - određeni lijekovi koji utječu na živčani sustav.
This medicine has been shown to reduce blood sugar, which may help to prevent complications from your diabetes. 
Pokazalo se da ovaj lijek smanjuje razinu šećera u krvi, što bi moglo pomoći u sprečavanju komplikacija uzrokovanih šećernom bolešću.
Studies in animals have shown reproductive toxicity at high doses (see section 5.3). 
Ispitivanja na životinjama pokazala su reproduktivnu toksičnost pri visokim dozama (vidjeti dio 5.3).
Information regarding overdose with vildagliptin is limited. 
Informacije o predoziranju vildagliptinom su ograničene.
Due to lack of human data, Jalra should not be used during pregnancy. 
Zbog nedovoljno podataka u ljudi, Jalra se ne smije primjenjivati tijekom trudnoće.
Vildagliptin cannot be removed by haemodialysis. 
Vildagliptin se ne može ukloniti hemodijalizom.
If you stop taking Jalra 
Ako prestanete uzimati Jalru
Other medicines and Jalra 
Drugi lijekovi i Jalra
• if you suffer from heart failure. 
• ako bolujete od zatajivanja srca.
If you think you may be allergic to vildagliptin or any of the other ingredients of Jalra, do not take this medicine and talk to your doctor. 
Ako mislite da biste mogli biti alergični na vildagliptin ili bilo koji od ostalih sastojaka Jalre, nemojte uzeti ovaj lijek i porazgovarajte sa svojim liječnikom.
C] vildagliptin, approximately 85% of the dose was excreted into the urine and 15% of the dose is recovered in the faeces. 
C] vildagliptina oko 85% doze se izlučuje u mokraću, a 15% doze pronađeno je u stolici.
Information on the likely symptoms of overdose was taken from a rising dose tolerability study in healthy subjects given Jalra for 10 days. 
Informacije o mogućim simptomima predoziranja uzete su iz ispitivanja podnošljivosti povećanja doze u zdravih ispitanika koji su primali Jalru tijekom 10 dana.
OUTER CARTON OF MULTIPACK (INCLUDING BLUE BOX) 
KUTIJA VIŠESTRUKOG PAKIRANJA (UKLJUČUJUĆI PLAVI OKVIR)
In vitro data in human kidney microsomes suggest that the kidney may be one of the major organs contributing to the hydrolysis of vildagliptin to its major inactive metabolite, LAY151. 
In vitro podaci na humanim bubrežnim mikrosomima navode na zaključak da bubreg može biti jedan od glavnih organa koji doprinosi hidrolizi vildagliptina u njegov glavni neaktivni metabolit, LAY151.
INTERMEDIATE CARTON OF MULTIPACK (WITHOUT BLUE BOX) 
MEĐUPAKIRANJE VIŠESTRUKOG PAKIRANJA (BEZ PLAVOG OKVIRA)
Jalra is not recommended for use in children and adolescents (< 18 years). 
Jalra se ne preporučuje za primjenu u djece i adolescenata (<18 godina).
Jalra contains lactose (milk sugar). 
Jalra sadrži laktozu (mliječni šećer).
Pharmacotherapeutic group: Drugs used in diabetes, dipeptidyl peptidase 4 (DPP-4) inhibitors, ATC code: A10BH02 
Farmakoterapijska skupina: Lijekovi za liječenje šećerne bolesti, inhibitori dipeptidil peptidaze 4 (DPP-4), ATK oznaka: A10BH02
• if you have moderate or severe kidney disease (you will need to take a lower dose of Jalra). 
• ako imate umjerenu do tešku bolest bubrega (trebat ćete uzeti nižu dozu Jalre).
• Do not use this medicine after the expiry date which is stated on the blister and the carton after 
• Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na blisteru i kutiji iza
What Jalra contains 
Što Jalra sadrži
The active substance of Jalra, vildagliptin, belongs to a group of medicines called “oral antidiabetics”. 
Djelatna tvar Jalre, vildagliptin, pripada skupini lijekova koji se nazivaju „oralni antidijabetici“.
Vildagliptin is indicated in the treatment of type 2 diabetes mellitus in adults: 
Vildagliptin je indiciran u liječenju šećerne bolesti tipa 2 u odraslih:
Use of vildagliptin has been associated with a risk of developing acute pancreatitis. 
Primjena vildagliptina bila je povezana s rizikom od razvoja akutnog pankreatitisa.
Excipient with known effect: Each tablet contains 47.82 mg lactose (anhydrous). 
Pomoćna tvar s poznatim učinkom: svaka tableta sadrži 47,82 mg laktoze (bezvodne).
How Jalra works 
Kako Jalra djeluje
Jalra 50 mg tablets are round, white to light yellowish and flat, with “NVR” on one side and “FB” on the other. 
Jalra 50 mg tablete su okrugle, bijele do svijetložućkaste i ravne, s oznakom „NVR“ na jednoj strani i „FB“ na drugoj strani.
* p< 0.05 for comparison versus placebo 
* p< 0,05 za usporedbu naspram placeba
Oral use Jalra can be administered with or without a meal (see also section 5.2). 
Jalra se može uzimati uz obrok ili bez obroka (vidjeti također dio 5.2).
• Store in the original package in order to protect from moisture. 
• Čuvati u originalnom pakiranju radi zaštite od vlage.
LAY151 concentrations were approximately 2-3-fold higher than in patients with severe renal impairment. 
Koncentracije LAY151 bile su otprilike 2-3 puta više nego u bolesnika s teškim oštećenjem bubrega.
A greater proportion of cases were reported when vildagliptin was administered in combination with an angiotensin converting enzyme inhibitor (ACE-Inhibitor). 
Veći udio slučajeva je zabilježen kada se vildagliptin davao u kombinaciji s inhibitorom angiotenzin konvertirajućeg enzima (ACE-inhibitor).
White to light yellowish, round (8 mm diameter), flat-faced, bevelled-edge tablet. 
Bijela do svijetložućkasta, okrugla (promjera 8 mm), ravna tableta sa zaobljenim rubovima.
7 tablets 14 tablets 28 tablets 30 tablets 56 tablets 60 tablets 90 tablets 112 tablets 180 tablets 336 tablets 
7 tableta 14 tableta 28 tableta 30 tableta 56 tableta 60 tableta 90 tableta 112 tableta 180 tableta 336 tableta
The European Medicines Agency has waived the obligation to submit the results of studies with vildagliptin in all subsets of the paediatric population with type 2 diabetes mellitus (see section 4.2 for information on paediatric use). 
Europska agencija za lijekove izuzela je obvezu podnošenja rezultata ispitivanja lijeka vildagliptin u svim podskupinama pedijatrijske populacije za šećernu bolest tipa 2 (vidjeti dio 4.2 za informacije o pedijatrijskoj primjeni).
Monotherapy placebo controlled studies 
Ispitivanja monoterapije kontrolirane placebom
It helps to control the level of sugar in the blood. 
Pomaže u kontroliranju razine šećera u krvi.
Patients who experience dizziness as an adverse reaction should avoid driving vehicles or using machines. 
Bolesnici koji osjete omaglicu kao nuspojavu trebaju izbjegavati upravljanje vozilima ili rad na strojevima.
* p< 0.05 for comparison versus placebo + comparator 
* p<0,05 za usporedbu naspram placebo + komparator
Glucagon is a substance which triggers the production of sugar by the liver, causing the blood sugar level to rise. 
Glukagon je tvar koja potiče stvaranje šećera u jetri, što uzrokuje porast razine šećera u krvi.
Animal studies have shown excretion of vildagliptin in milk. 
Ispitivanja na životinjama pokazala su da se vildagliptin izlučuje u mlijeko.
The increased incidence of these tumours in mice is considered not to represent a significant risk to humans based on the lack of genotoxicity of vildagliptin and its principal metabolite, the occurrence of tumours only in one species and the high systemic exposure ratios at which tumours were observed. 
Smatra se da povećana incidencija tih tumora u miševa ne predstavlja značajan rizik za ljude na temelju nepostojanja genotoksičnosti vildagliptina i njegovog glavnog metabolita, zbog pojave tumora samo u jedne vrste te velikih omjera sustavne izloženosti kod kojih su tumori zapaženi.
Jalra should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. 
Jalra se ne smije primjenjivati u bolesnika sa šećernom bolešću tipa 1 ili za liječenje dijabetičke ketoacidoze.
The safety and efficacy of vildagliptin as triple oral therapy in combination with metformin and a thiazolidinedione have not been established. 
Nije ustanovljena sigurnost i djelotvornost vildagliptina kao trojne oralne terapije u kombinaciji s metforminom i tiazolidindionom.
The safety and efficacy of Jalra in children and adolescents (< 18 years) have not been established. 
Sigurnost i djelotvornost Jalre u djece i adolescenata (<18 godina) nisu još ustanovljene.
Vildagliptin was not associated with a change in left-ventricular function or worsening of pre-existing CHF. 
Vildagliptin nije bio povezan s promjenom u funkciji lijeve klijetke ili pogoršanjem već postojećeg KZS-a.
Vildagliptin was removed by haemodialysis to a limited extent (3% over a 3-4 hour haemodialysis session starting 4 hours post dose). 
Vildagliptin je bio uklonjen hemodijalizom u ograničenoj mjeri (3% tijekom hemodijalize u trajanju od 3-4 sata, a koja je počela 4 sata nakon doziranja).
The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP. 
Nositelj odobrenja obavljat će zadane farmakovigilancijske aktivnosti i intervencije, detaljno objašnjene u dogovorenom Planu upravljanja rizikom (RMP), a koji se nalazi u Modulu 1.8.2 Odobrenja za stavljanje lijeka u promet, te svim sljedećim dogovorenim ažuriranim verzijama RMP-a.
Patients who develop increased transaminase levels should be monitored with a second liver function evaluation to confirm the finding and be followed thereafter with frequent liver function tests until the abnormality(ies) return(s) to normal. 
Bolesnike u kojih se pojave povišene vrijednosti transaminaza treba pratiti provođenjem druge procjene jetrene funkcije s ciljem potvrđivanja nalaza te nakon toga kontrolirati čestim testovima jetrene funkcije sve dok se abnormalna(e) vrijednost(i) ne vrati(e) na normalu.
Following oral administration of [ 
Nakon peroralne primjene [
In the subgroup with NYHA class III, the decrease in HbA1c compared to placebo was lower (difference 0.3%) but this conclusion is limited by the small number of patients (n=44). 
U podskupini s NYHA klasom III, smanjenje HbA1c u usporedbi s placebom bilo je manje (razlika 0,3%), ali taj je zaključak ograničen malim brojem bolesnika (n=44).
• Do not use any Jalra pack that is damaged or shows signs of tampering. 
• Jalra se ne smije upotrijebiti ako je kutija oštećena ili postoje vidljivi znakovi otvaranja.
Therefore Jalra should be used with caution in these patients (see also sections 4.2, 5.1 and 5.2). 
Zbog toga se u tih bolesnika Jalra treba primjenjivati s oprezom (vidjeti također dijelove 4.2, 5.1 i 5.2).
At 600 mg, one subject experienced oedema of the feet and hands, and increases in creatine phosphokinase (CPK), aspartate aminotransferase (AST), C-reactive protein (CRP) and myoglobin levels. 
Pri dozi od 600 mg u jednog je ispitanika došlo do edema stopala i šaka te porasta razina kreatin fosfokinaze (CPK), aspartat aminotransferaze (AST), C-reaktivnog proteina (CRP) i mioglobina.
Do not take Jalra: 
Nemojte uzimati Jalru:
• Angioedema (rare: may affect up to 1 in 1,000 people): Symptoms include swollen face, tongue or throat, difficulty swallowing, difficulties breathing, sudden onset rash or hives, which may indicate a reaction called “angioedema”. 
• Angioedem (rijetko: mogu se javiti u do 1 in 1000 osoba): simptomi uključuju otečeno lice, jezik ili grlo, otežano gutanje, otežano disanje, iznenadno izbijanje osipa ili koprivnjače, što može upućivati na reakciju zvanu „angioedem“.
Clinical experience in patients with NYHA functional class III treated with vildagliptin is still limited and results are inconclusive (see section 5.1). 
Klinička iskustva u bolesnika s NYHA funkcionalnom klasom III liječenih vildagliptinom još uvijek su ograničena te se na temelju rezultata ne mogu donositi zaključci (vidjeti dio 5.1).
Ethnic group Limited data suggest that race does not have any major influence on vildagliptin pharmacokinetics. 
Ograničeni podaci navode na zaključak da rasa nema nikakav značajniji utjecaj na farmakokinetiku vildagliptina.
Some patients have had the following side effects while taking Jalra, metformin and a sulphonylurea: • Common: Dizziness, tremor, weakness, low blood glucose, excessive sweating 
Neki su bolesnici imali sljedeće nuspojave kada su uzimali Jalru, metformin i sulfonilureju: • Često: omaglica, tremor, slabost, niska razina glukoze u krvi, pojačano znojenje
No clinically relevant differences in the pharmacokinetics of vildagliptin were observed between male and female healthy subjects within a wide range of age and body mass index (BMI). 
U farmakokinetici vildagliptina nisu zapažene klinički značajne razlike između zdravih ispitanika muškog i ženskog spola unutar širokog raspona dobi i indeksa tjelesne mase (BMI).
The major metabolite (LAY 151) is pharmacologically inactive and is the hydrolysis product of the cyano moiety, accounting for 57% of the dose, followed by the glucuronide (BQS867) and the amide hydrolysis products (4% of dose). 
Glavni metabolit (LAY 151) je farmakološki neaktivan i produkt je hidrolize cijano dijela molekule, na što otpada 57% doze, nakon čega slijedi glukuronid (BQS867) i produkt hidrolize amida (4% doze).